Cargando…

D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring

A 67-year-old female presented with severe hypoglycaemia with a blood glucose of 34mg/dl 5 hours after having dinner. She did not have diabetes and had no access to oral hypoglycaemic agents, insulin, or any other drug known to cause hypoglycaemia. She was a known case of primary hypothyroidism euth...

Descripción completa

Detalles Bibliográficos
Autores principales: Batra, Chandar M, Kumar, Kiran, Goyal, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067842/
http://dx.doi.org/10.4103/2230-8210.342324
_version_ 1784700097772126208
author Batra, Chandar M
Kumar, Kiran
Goyal, Monica
author_facet Batra, Chandar M
Kumar, Kiran
Goyal, Monica
author_sort Batra, Chandar M
collection PubMed
description A 67-year-old female presented with severe hypoglycaemia with a blood glucose of 34mg/dl 5 hours after having dinner. She did not have diabetes and had no access to oral hypoglycaemic agents, insulin, or any other drug known to cause hypoglycaemia. She was a known case of primary hypothyroidism euthyroid on treatment. The physical examination was unremarkable. Her liver, renal functions, thyroid, and adrenal functions were normal. At blood sugar of 23 mg/dl, her serum insulin was 24000uU/ml (normal<3uU/ml) and c-peptide was 16.2 ng/ml (normal 0-0.6ng/ml) which were very high. As the serum insulin levels were very high insulin autoimmune syndrome was suspected. Insulin autoantibodies were positive 87.2 units/ml (normal<12). Imaging with contrast-enhanced computerized tomography (CECT Abdomen), endoscopic ultrasonography, 68 gallium octreotide dotanoc whole-body PET -CT scan did not reveal any pancreatic or extra-pancreatic tumour. Autoimmune insulin syndrome (IAS) was diagnosed. She was started on high dose prednisolone, diazoxide and octreotide in addition to low carbohydrate meals. Hypoglycaemic episodes continued for 1 month despite this therapy. Remission was achieved only after 2 doses of Rituximab 1 gram infusion were given. Serum insulin levels were reduced to 230uU units from 24000uU/ml, and the patient's hypoglycaemic and hyperglycaemic episodes were normalized. We used continuous glucose monitoring using the Freestyle Libre glucose monitoring system, and the management of the patient was greatly facilitated with this.
format Online
Article
Text
id pubmed-9067842
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-90678422022-05-05 D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring Batra, Chandar M Kumar, Kiran Goyal, Monica Indian J Endocrinol Metab Meet the Expert Cases…esicon 2021 A 67-year-old female presented with severe hypoglycaemia with a blood glucose of 34mg/dl 5 hours after having dinner. She did not have diabetes and had no access to oral hypoglycaemic agents, insulin, or any other drug known to cause hypoglycaemia. She was a known case of primary hypothyroidism euthyroid on treatment. The physical examination was unremarkable. Her liver, renal functions, thyroid, and adrenal functions were normal. At blood sugar of 23 mg/dl, her serum insulin was 24000uU/ml (normal<3uU/ml) and c-peptide was 16.2 ng/ml (normal 0-0.6ng/ml) which were very high. As the serum insulin levels were very high insulin autoimmune syndrome was suspected. Insulin autoantibodies were positive 87.2 units/ml (normal<12). Imaging with contrast-enhanced computerized tomography (CECT Abdomen), endoscopic ultrasonography, 68 gallium octreotide dotanoc whole-body PET -CT scan did not reveal any pancreatic or extra-pancreatic tumour. Autoimmune insulin syndrome (IAS) was diagnosed. She was started on high dose prednisolone, diazoxide and octreotide in addition to low carbohydrate meals. Hypoglycaemic episodes continued for 1 month despite this therapy. Remission was achieved only after 2 doses of Rituximab 1 gram infusion were given. Serum insulin levels were reduced to 230uU units from 24000uU/ml, and the patient's hypoglycaemic and hyperglycaemic episodes were normalized. We used continuous glucose monitoring using the Freestyle Libre glucose monitoring system, and the management of the patient was greatly facilitated with this. Wolters Kluwer - Medknow 2022-03 /pmc/articles/PMC9067842/ http://dx.doi.org/10.4103/2230-8210.342324 Text en Copyright: © 2022 Indian Journal of Endocrinology and Metabolism https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Meet the Expert Cases…esicon 2021
Batra, Chandar M
Kumar, Kiran
Goyal, Monica
D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring
title D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring
title_full D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring
title_fullStr D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring
title_full_unstemmed D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring
title_short D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring
title_sort d1 mte1 case 1: steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring
topic Meet the Expert Cases…esicon 2021
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067842/
http://dx.doi.org/10.4103/2230-8210.342324
work_keys_str_mv AT batrachandarm d1mte1case1steroidrefractoryinsulinautoimmunesyndrometreatedwithrituximabandcontinuousglucosemonitoring
AT kumarkiran d1mte1case1steroidrefractoryinsulinautoimmunesyndrometreatedwithrituximabandcontinuousglucosemonitoring
AT goyalmonica d1mte1case1steroidrefractoryinsulinautoimmunesyndrometreatedwithrituximabandcontinuousglucosemonitoring